Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis subsp. lactis J12
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
*Bifidobacterium animalis* subsp. *lactis* J12 is a probiotic strain being investigated for its therapeutic potential in managing atopic dermatitis (AD). It has been studied in two primary formulations: oral live cells (J12L) and topical fermented supernatants (J12S). The oral formulation exerts systemic effects via the gut-skin axis, enhancing gut microbiota alpha diversity and modulating the immune system to reduce epidermal thickness and mast cell infiltration. The topical formulation provides local anti-inflammatory effects and protects the skin barrier. Both delivery routes have demonstrated the ability to reduce pro-inflammatory cytokines such as IL-4 and IL-17 while increasing the proportion of splenic regulatory T cells (Tregs). In preclinical mouse models, J12 has shown superior efficacy compared to other probiotic strains, highlighting its versatile potential as a live biotherapeutic for inflammatory skin conditions.
- Other names
- Bifidobacterium animalis J12B. animalis subsp. lactis J12
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on bifidobacterium animalis subsp. lactis J12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis subsp. lactis J12.